{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:42Z","timestamp":1786119522688,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/jcp.0b013e3181e69042","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T05:51:38Z","timestamp":1277185898000},"page":"425-430","source":"Crossref","is-referenced-by-count":24,"title":["A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia"],"prefix":"10.1097","volume":"30","author":[{"given":"Stephen M.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Newcomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Potkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Weiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Watsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia O.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.2007.00992.x","article-title":"Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?","volume":"115","author":"Buckley","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R2-15-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.","volume":"162","author":"Milev","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R3-15-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms.","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"key":"R5-15-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-15-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophr Res"},{"key":"R7-15-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R8-15-20210128","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/ajp.152.6.827","article-title":"Patient response and resource management: another view of clozapine treatment of schizophrenia.","volume":"152","author":"Carpenter","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R9-15-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0920-9964(90)90045-9","article-title":"Effects of anticholinergic medication on memory in schizophrenia.","volume":"3","author":"Strauss","year":"1990","journal-title":"Schizophr Res"},{"key":"R10-15-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: a problem that will not go away.","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R11-15-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.161.3.473","article-title":"Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.","volume":"161","author":"Robinson","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R12-15-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus.","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R13-15-20210128","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145709000352","article-title":"Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.","volume":"12","author":"Potkin","year":"2009","journal-title":"Int J Neuropsychopharmacology"},{"key":"R14-15-20210128","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality-of-Life scale: an instrument for rating the schizophrenic deficit syndrome.","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr Bull"},{"key":"R15-15-20210128","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.","volume":"65","author":"Addington","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R16-15-20210128","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event.","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"R17-15-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMc0903274","article-title":"Calculation of number needed to treat.","volume":"361","author":"Suissa","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201008000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:29:33Z","timestamp":1786040973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201008000-00015"}},"subtitle":["A 40-Week Randomized, Double-Blind Study of Ziprasidone Versus Haloperidol Followed by a 3-Year Double-Blind Extension Trial"],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181e69042","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}